

requirements, FDA provides relief for small businesses in the form of exemptions and partial exemptions set forth in §§ 1.327 and 1.1305. FDA also help small businesses comply with our

requirements through our Regional Small Business Representatives and via the agency’s website at <https://www.fda.gov/industry/small-business-assistance>. The regulations also allow

for requests to modify or exempt requirements and for waivers.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN <sup>1</sup>

Activity; 21 CFR section	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
Requests for modified requirements and exemptions; 1.1370 .....	5	1	5	10	50
Requests for waivers; 1.1415 through 1.1425 .....	15	1	15	10	150
Total .....			20		200

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN <sup>1</sup>

Activity; 21 CFR section	Number of recordkeepers	Number of records per recordkeeper	Total annual records	Average burden per recordkeeping	Total hours
Records maintenance; 1.337, 1.345, and 1.352 .....	379,493	1	379,493	7 .....	2,656,451
Create and establish traceability plan; 1.1315 .....	212,368	1	212,368	8 .....	1,698,944
Records for harvesting or cooling; 1.1325 .....	9,570	575	5,502,750	0.07 (4 minutes) .....	385,193
Records for initial packer; 1.1330 .....	4,313	865	3,730,745	0.07 (4 minutes) .....	261,152
Records for first land-based receiver; 1.1335 .....	367	1,471	539,857	0.03 (2 minutes) .....	16,196
Records for shipper and receiver; 1.1340 and 1.1345 Transformer; 1.1350 .....	502,000	5,900	2,961,800,000	0.006 (20 seconds) .....	17,770,800
	8,574	1,101	9,439,974	0.03 (2 minutes) .....	283,199
Total .....			2,981,605,187		23,071,935

<sup>1</sup> There are no capital costs or operating and maintenance costs associated with this collection of information.

The revised estimated annual burden reflects updates to the consideration of burden. We believe that the burden for part 1, subpart J was inadvertently omitted from the previous approval, so we are adding it here. However, we believe some of the considerations for burden should have been incorporated with PRA activities instead of being considered independently. Lastly, considerations of burden for §§ 1.1465(a) and 1.1455(c)(3)(ii) do not apply to the PRA so we have removed this burden. Section 1.1465(a) is a general solicitation for comment, which is not considered “information” under the PRA regulations (5 CFR 1320.3(h)(4)). Activities under § 1.1455(c)(3)(ii) applies to an investigation, audit, or action after a case file is opened for a specific party, which is exempt from OMB review as discussed earlier in this document (5 CFR 1320.4(a)(2)).

Our estimated burden for the information collection reflects an overall increase of 4,227,299 hours but a corresponding decrease of 4,973,420 records. We attribute the increase in hours to the return of burden for part 1, subpart J along with adjustments to the average burden per recordkeeping. We attribute the decrease in records due to

the reconsideration of activities such as learning new requirements and training staff and incorporating the time for these activities as part of the actual information collection.

**Grace R. Graham,**  
Deputy Commissioner for Policy, Legislation, and International Affairs.  
[FR Doc. 2026–11760 Filed 6–10–26; 8:45 am]  
BILLING CODE 4164–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2026–N–4492]

**Drug Repurposing for Unmet Medical Needs; Request for Information; Extension of Comment Period**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; request for information; establishment of a public docket.

**SUMMARY:** The Food and Drug Administration (FDA, the Agency, or we) is extending the comment period for the notice entitled “Drug Repurposing for Unmet Medical Needs; Request for Information” that appeared in the

**Federal Register** of May 12, 2026 (91 FR 25897). In the notice, FDA requested comments to solicit input on FDA’s efforts with respect to drug repurposing to address unmet medical needs. The Agency is taking this action to allow interested persons additional time to submit comments.

**DATES:** FDA is extending the comment period for the notice published May 12, 2026 (91 FR 25897). Submit either electronic or written comments, data, or information by July 13, 2026.

**ADDRESSES:** You may submit comments, data, and information as follows. Please note that late, untimely filed comments will not be considered. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of July 13, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically,

including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

#### Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

*Instructions:* All submissions received must include the Docket No. FDA-2026-N-4492 for "Drug Repurposing for Unmet Medical Needs; Request for Information." Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- *Confidential Submissions—*To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information

redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.

*Docket:* For access to the docket to read background documents or the electronic and written/paper comments received, go to <https://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500.

#### FOR FURTHER INFORMATION CONTACT:

Caroline Huang, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6117, Silver Spring, MD 20993-0002, [drugrepurposing@fda.hhs.gov](mailto:drugrepurposing@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of May 12, 2026 (91 FR 25897), FDA published a notice with a 30-day comment period to request comments on the document entitled "Drug Repurposing for Unmet Medical Needs; Request for Information." FDA issued this request for information to solicit input on potential priority disease areas and potential candidates for drug repurposing, with a focus on FDA-approved drugs for which there appears to be no commercial interest in adding a new use through a supplement to a new drug application (supplemental application).

FDA is extending the comment period for 30 days, until July 13, 2026. The Agency believes that a 30-day extension will allow adequate time for interested persons to submit comments.

#### Grace R. Graham,

*Deputy Commissioner for Policy, Legislation, and International Affairs.*

[FR Doc. 2026-11691 Filed 6-10-26; 8:45 am]

**BILLING CODE 4164-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Solicitation of Nominations for Membership on the Presidential Advisory Council on HIV/AIDS

**AGENCY:** Office of the Assistant Secretary for Health, Office of Infectious Disease and HIV/AIDS Policy, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice; Solicitation of nominations for appointment to Presidential Advisory Council on HIV/AIDS (PACHA).

**SUMMARY:** The Office of the Assistant Secretary for Health (OASH) is seeking nominations for membership on the Presidential Advisory Council on HIV/AIDS (referred to as PACHA and/or the Council). The PACHA is a federal advisory committee within the U. S. Department of Health and Human Services (HHS). Management support for the activities of this Council is the responsibility of the Office of the Assistant Secretary for Health (OASH). The qualified individuals will be nominated by the Secretary of the U.S. Department of Health and Human Services for appointment to the PACHA. Members of the Council, including the Chair, are appointed by the Secretary. Members are invited to serve for overlapping terms of up to four years. The Council was established to provide advice, information, and recommendations to the Secretary regarding programs, policies, and research to promote effective treatment, prevention and cure of HIV and AIDS, including considering common comorbidities, as needed to promote effective HIV diagnosis, treatment, prevention, and quality care services. The functions of the Council are solely advisory in nature. A copy of the PACHA charter that describes its structure and functions and lists of the current members can be reviewed on the PACHA website at: <https://www.hiv.gov/federal-response/pacha/about-pacha>.

**DATES:** Nominations for membership on the PACHA must be received no later than thirty days from publication. Packages received after this time will not be considered for the current membership cycle.

**ADDRESSES:** All nominations should be emailed in one email to [pacha@hhs.gov](mailto:pacha@hhs.gov) with the subject line "PACHA Application 2026."

**FOR FURTHER INFORMATION CONTACT:** CDR Neelam Gazarian, Acting Designated Federal Officer, U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health,